What question did this study set out to answer?

To develop an AI companion that assists clinicians in delivering evidence-based care for IBD effectively.

January 23, 2026Journal of Crohn s and Colitis0 citations

DOP096ChatIBD: AI Companion for Inflammatory Bowel Disease (IBD) Clinicians

BGBeatriz GrosWestern General Hospital NPNikolas PlevrisWestern General Hospital CCC S ChuahInstitute of Infection and Immunity

Key Points

To develop an AI companion that assists clinicians in delivering evidence-based care for IBD effectively.
Developed ChatIBD, an AI tool for clinicians managing IBD care.
Integrated retrieval-augmented generation and curated clinical guidelines.
Included multilingual support for broader accessibility.
Conducted beta testing to evaluate accuracy and user queries.
Received 2,642 queries from 578 users in 54 countries after launch.
Achieved over 95% accuracy across 400 reviewed responses.
Demonstrated high usage in English and Spanish, with significant user engagement in multiple countries.

Abstract

Abstract Background Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a growing global health challenge. Managing IBD is increasingly complex, with rapidly evolving treatment options, proliferating guidelines, and varying regional practices. Clinicians face limited time to remain current, and access to IBD expertise is uneven worldwide. Methods ChatIBD (www.chatibd.com) is a new artificial intelligence (AI) tool, designed by IBD clinicians, to support healthcare professionals delivering IBD care. By combining retrieval-augmented generation with curated guidelines (30 guidelines from ECCO, BSG, AGA, ACG, ESPGHAN), ChatIBD provides clear, evidence-based answers to practical clinical questions, always referenced to trusted sources and tailored to the user’s region. A “deep research” mode extends searches to emerging literature, ensuring clinicians can keep pace with innovation. Safety and accuracy are reinforced through an integrated dosing database built from European Medicines Agency (EMA) product information, delivering regulator-approved induction and maintenance regimens. ChatIBD’s multilingual capability (English and Spanish in testing) extends accessibility across diverse settings. ChatIBD query handling architecture is shown in Figure 1. Results ChatIBD launched in October 2025. Since going live, a total of 2,642 queries, in 19 different languages were submitted from 578 registered users residing in 54 different countries. The top 5 countries were UK (n = 617 queries), Spain (n = 362 queries), USA (n = 270 queries), Brazil (n = 182 queries) and Germany (n = 119 queries), respectively. Top 5 languages were English (70.1%), Spanish (15.4%), Portuguese (6.3%), German (3.7%) and Dutch (2.7%), respectively. The domains and intent of clinical queries are shown in Table 1. In the current beta testing phase, ChatIBD has demonstrated 95% accuracy across 400 reviewed responses. Conclusion By making specialist-level knowledge accessible, ChatIBD has the potential to reduce unwarranted variation in care, empower clinicians, and support better outcomes for people with IBD - while offering a scalable digital health model that can extend to other disease areas/specialties. Multilingual, global access also helps democratise access to information worldwide especially in developing countries where we are seeing a rapid increase in the incidence and prevalence of IBD. Conflict of interest: Gros, Beatriz: Beatriz Gros has served as a speaker for Abbvie, Johnson and Johnson, Takeda, Roche, Gilead, Pfizer and Galapagos and has served as an advisor for Roche, Gilead, Abbvie, Galapagos and Takeda Plevris, Nikolas: No conflict of interest Chuah, Cher Shiong: No conflict of interest

Ask AI

Helpful

Bookmark

View Full Paper